Enter your login e-mail to the account
Search
- New trends in metastatic hormone-sensitive prostate cancer treatment
prof. MUDr. Ján Kliment, CSc.
(2/2020, Interdisciplinary consilium )
- Rational use of psychotropic drugs in oncology – selected indications, interactions, tips for practice
PharmDr. Jana Gregorová, MUDr. Petra Holečková, Ph.D., MBA
(4/2017, Review articles )
- One morning, when Gregor Samsa woke from troubled dreams
MUDr. Veronika Vestenická, PhD.
(2/2017 )
- Immunotherapy in the treatment of urological malignancies
MUDr. Jana Katolická, Ph.D., MUDr. Petr Filipenský, Ph.D.
(3/2019, Review articles ) - New treatment options in hormone-sensitive prostate cancer
MUDr. Otakar Čapoun, Ph.D., FEBU
(5/2019, Review articles ) - Drug interactions in the therapy of bladder cancer
Mgr. Tereza Medková, Mgr. Tereza Vaňková
(2/2026, Drug interaction ) - Drug interactions in the treatment of kidney cancer
Mgr. Lucie Kovářová, PharmDr. Milada Halačová, Ph.D.
(3/2026, Drug interaction ) - Drug interactions in urology in patients with hypertension
PharmDr. Helena Šťastná Koblihová, Mgr. Jana Gallusová, PharmDr. Dalibor Černý, Ph.D., PharmDr. Milada Halačová, Ph.D.
(3/2024, Drug interaction ) - Is age the limitation of metastatic treatment prostate cancer?
MUDr. Jana Katolická, Ph.D.
(5/2018, Review articles ) - Consequences of genitourinary malignancies therapy on cardiovascular system
Prof. MUDr. Beata Mladosievičová, CSc., MUDr. Lucia Petríková, RNDr. Zuzana Poljak Valášková, Ph.D.
(5/2018, Review articles ) - Therapy of prostate cancer in elderly patients
MUDr. Otakar Čapoun, Ph.D., FEBU
(3/2022, Review articles ) - New diagnostic options and prognosis prediction of urinary bladder cancer
MUDr. Milan Kral, Ph.D., MUDr. David Hradil, MUDr. Šarka Kudlačkova, MUDr. Aleš Vidlář, Ph.D., FEBU, doc. MUDr. Vladimír Študent, Ph.D.
(2/2017, Review articles ) - Non-metastatic castration-resistant prostate cancer
MUDr. Jana Katolická, Ph.D.
(2/2022, Review articles ) - Photoprotection during antibiotic and antineoplastic treatment
MUDr. Jiří Ettler, MUDr. PharmDr. Jan Dvořák, MUDr. Filip Prusík, doc. MUDr. Karel Ettler, CSc.
(4/2021, Practical advice ) - PARP inhibitors in treating metastatic castration-resistant prostate cancer
MUDr. Igor Richter, Ph.D., doc. MUDr. Josef Dvořák, Ph.D., MUDr. Vladimír Šámal, Ph.D., MUDr. Jiří Bartoš, MBA, MUDr. Sofya Al-Samsam
(3/2023, Review articles ) - Current treatment management of non-metastatic castration-resistant prostate cancer
MUDr. Nikol Rušarová, MUDr. Hana Študentová, Ph.D.
(1/2020, Review articles ) - Prostate cancer – interaction potential of used drugs
PharmDr. Roman Goněc, PharmDr. Vojtěch Ondra, Doc. PharmDr. Jan Juřica, Ph.D.
(2/2025, Drug interaction ) - Drug interactions in urology – what to watch out for
PharmDr. Josef Suchopár, MUDr. Michal Prokeš, Štěpán Suchopár
(2/2020, Drug interaction ) - Systemic radiotherapy for prostate cancer with bone metastases
MUDr. Otakar Čapoun, FEBU
(3/2016, Review articles ) - Immunotherapy for prostate cancer
MUDr. Michal Podrazil, Ph.D., prof. MUDr. Radek Špíšek, Ph.D., prof. MUDr. Jiřina Bartůňková, DrSc.
(4/2016, Review articles ) - Treatment of non-metastatic castration-resistant prostate cancer
MUDr. Ivo Kocák, Ph.D.
(4/2020, Review articles ) - The role of ARTAs in treating metastatic castration-resistant prostate cancer
MUDr. PharmDr. Jan Dvořák
(2/2019, Review articles ) - Hematospermia
doc. MUDr. Jozef Marenčák, PhD.
(1/2019, Review articles ) - Have we found an optimal sequence in the treatment of metastatic castrationally-resistant prostate cancer?
MUDr. Tomaš Svoboda, Ph.D.
(1/2019, Review articles )
- Castration resistant prostate cancer in the year 2013
doc. MUDr. Jozef Marenčák, PhD.
(3/2013, Review articles ) - Proper selection of patients for Radium 223 and its role in metastatic castration-resistant prostate cancer treatment
JUDr. MUDr. Patrik Palacka, PhD., MPH, MBA, LL.M., MUDr. Ján Slopovský
(2/2021, Review articles ) - 18F-choline PET/CT in evaluation of therapeutic response of castration-resistant prostate cancer
Doc. MUDr. Soňa Balogová, PhD., MUDr. Lucia Noskovičová, MUDr. Lucia Kaliská FEBMN , MUDr. Marika Vereb, FEBMN, MUDr. Marek Bartovic
(3/2015, Review articles ) - Treatment of bone metastases in castration resistant prostate cancer – current view
doc. MUDr. Jozef Marenčák, PhD.
(3/2015, Review articles ) - Bratislavské onkologické dni, LVII. ročník – odborný program a abstrakty
Kolektív autorov
(S3/2020, Abstracts ) - Správa z konferencie Novinky z ASCO 2019
MUDr. Mária Rečková, PhD.
(3/2019, Events ) - Non-metastatic castration-resistant prostate cancer
JUDr. MUDr. Patrik Palacka, PhD., MPH, MBA, LL.M., MUDr. Ján Slopovský
(3/2019, Review articles ) - ENZALUTAMID V LIEČBE METASTATICKÉHO KARCINÓMU PROSTATY
doc. MUDr. Pavol Dubinský, PhD., MHA
(S1/2026, Editorial ) - The role of enzalutamide in the treatment of metastatic hormone-sensitive prostate cancer
MUDr. Lenka Barreto, FEBU
(S1/2026, Metastatický hormonálne senzitívny karcinóm prostaty ) - Systemic therapy of a patient with de novo metastatic prostate carcinomainitially
Doc. JUDr. MUDr. Patrik Palacka, PhD., MPH, MBA, LL.M.
(S1/2026, Metastatický hormonálne senzitívny karcinóm prostaty ) - Enzalutamid in the treatment of metastatic castration- resistant prostate cancer – case report
MUDr. Katarína Štefániková
(S1/2026, Metastatický hormonálne senzitívny karcinóm prostaty ) - Long-term control of metastatic hormone-sensitive prostate cancer with multiple liver metastases
MUDr. Zuzana Tomková, MUDr. Katarína Belánová
(S1/2026, Metastatický hormonálne senzitívny karcinóm prostaty ) - Lutetium-177-PSMA in therapy of metastatic prostate cancer
MUDr. Eva Takácsová, PhD.
(4/2022, Main topic ) - Immunotherapy and targeted treatment for metastatic, castration-resistant prostate cancer
MUDr. Ján Slopovský, JUDr. MUDr. Patrik Palacka, PhD., MPH, MBA, LL.M.
(4/2022, Main topic ) - Immunotherapy in prostate cancer
MUDr. Katarína Rejleková, PhD.
(5/2020, Review articles ) - Current treatment options for metastatic hormone-sensitive prostate cancer
MUDr. Jana Obertová, PhD.
(4/2023, Main topic ) - Review on castrate-resistant prostate carcinoma systemic therapy
Doc. JUDr. MUDr. Patrik Palacka, PhD., MPH, MBA, LL.M.
(4/2023, Main topic ) - A comprehensive view of the treatment of metastatic hormone sensitive prostate cancer
prof. MUDr. Ján Kliment, CSc., MUDr. Ing. Monika Kuzma, MBA
(5/2019, Main topic ) - Správa z XII. ročníka bardejovských onkologických dní 14. -16. jún 2023, Bardejovské Kúpele
MUDr. Lea Balážová
(4/2023, Events ) - Current possibilities and view of treatment of castration refractory metastatic prostate cancer
MUDr. Radovan Barilla, PhD.
(5/2019, Main topic ) - Castration resistant prostate cancer – something new in the year 2014?
doc. MUDr. Jozef Marenčák, PhD.
(4/2014, Main topic ) - Biologic therapy in older patients
MUDr. Mária Novisedláková
(3/2017, Main topic ) - 5. konferencia Slovenskej spoločnosti radiačnej onkológie – odborný program a abstrakty
Kolektív autorov
(S2/2022, Abstracts ) - Správy z podujatia ASCO Chicago 2014
prof. MUDr. Stanislav Špánik, CSc., MUDr. Mária Rečková, MUDr. Patrik Palacka, PhD. MPH, MBA
(4/2014, Events ) - Bratislavské onkologické dni 63. ročník 30. 9. – 2. 10. 2026, Bratislava
(S3/2026, Abstracts ) - Metastatický kastračne rezistentný karcinóm prostaty
prof. MUDr. Ján Kliment, CSc.
(S1/2019, Editorial ) - Treatment of patient with metastatic castrate refractory prostate cancer after androgen deprivation therapy failure
MUDr. Jozef Babeľa, PhD.
(S1/2019, Case reports ) - Death following brain metastases evolvement in patient with metastatic castration resistant adenocarcinoma of prostate treated by enzalutamide with low level PSA
MUDr. Roman Tomaškin, PhD.
(S1/2019, Case reports ) - Treatment of metastatic castrate-resistant prostate cancer with enzalutamide
MUDr. Klaudia Gočárová, PhD.
(S1/2019, Case reports ) - Favourable therapeutic response of enzalutamide in patient with metastatic castration resistant prostate cancer
MUDr. Martin Romančík, PhD., MPH
(S1/2019, Case reports ) - Enzalutamide in the treatment of metastatic castration-resistant prostate cancer
MUDr. Andrej Rosík, MUDr. Ladislav Slobodník
(S1/2019, Case reports ) - Enzalutamide in treatment of the metastatic castration resistant prostate cancer
Doc. MUDr. Jozef Marenčák, PhD.
(6/2017, Drugs & drug classes ) - Bratislavské onkologické dni LXI. ročník- Odborný program a abstrakty
Kolektív autorov
(S3/2024, Abstracts ) - Metastatický hormonálne senzitívny karcinóm prostaty
prof. MUDr. Ján Kliment, CSc.
(S5/2024, Editorial ) - Current trends in the treatment of metastatic hormone-sensitive prostate cancer – a case report
MUDr. Abdullah Dammak, MBA, MUDr. Bc. Viera Dammak, MBA
(S5/2024, Case reports ) - Treatment of a patient with metastatic hormone-sensitive prostate cancer – case report
MUDr. Peter Ščešňák
(S5/2024, Case reports ) - Enzalutamide in the treatment of metastatic castration-resistant prostate cancer
MUDr. Andrej Rosík, MUDr. Marika Hladká, MUDr. Ladislav Slobodník
(S5/2024, Case reports ) - Efficacy and tolerance of ARTA treatment in a patient with metastatic hormone-sensitive prostate cancer
MUDr. Filip Kohútek, PhD.
(S5/2024, Case reports ) - Efficacy of darolutamide in the treatment castration sensitive prostate cancer
MUDr. Peter Leško, PhD.
(4/2024, Drugs & drug classes ) - Metastatic prostate cancer - new therapeutical approaches
MUDr. Patrik Palacka, PhD., MPH, MBA, Mgr. Soňa Herudová
(2/2015, Review articles ) - Online decision support tools in oncology
MUDr. Ján Slopovský, JUDr. MUDr. Patrik Palacka, PhD., MPH, MBA, LL.M., MUDr. Natália Pazderová, MUDr. Benjamin Špánik, MUDr. Eva Zomborská, MUDr. Tomáš Šálek, MUDr. Štefan Pörsök, PhD.
(4/2020, Review articles ) - Správa z Best of ASCO® Slovakia 2012
MUDr. Mária Rečková
(6/2012, Events ) - Critical moments in the treatment of prostate cancer
MUDr. Marián Bernát
(6/2019, Review articles ) - First-line treatment of metastatic castration-sensitive prostate cancer
JUDr. MUDr. Patrik Palacka, PhD., MPH, MBA, LL.M., MUDr. Ján Slopovský
(3/2022, Review articles ) - 4. konferencia Slovenskej spoločnosti radiačnej onkológie 26. – 27. apríl 2018, Ružomberok
Kolektív autorov
(S2/2018, Supplement ) - Bratislavské onkologické dni LV. ročník
Kolektív autorov
(S4/2018, Supplement ) - Current options for the use of PARP inhibitors in patients with metastatic castration-resistant prostate cancer with impaired DNA repair mechanisms
MUDr. Radovan Barila, PhD.
(3/2025, Review articles ) - Abiraterone in treatment of metastatic castrate resistant prostate cancer
prof. MUDr. Ján Kliment, CSc.
(2/2014, Drugs & drug classes ) - Management of sequential and combined treatment of a patient with metastatic prostate cancer
Doc. MUDr. Ján Breza, PhD.
(S1/2020, Case reports ) - Treatment of enzalutamide in the therapy of metastatic castration-resistant prostate cancer in postchemoindication
MUDr. Alexandra Szabová
(S1/2020, Case reports ) - Treatment of patient with metastatic prostate cancer – from sensitive to castration resistant disease – case report
MUDr. Vladimír Lenko, PhD., FEBU
(S1/2020, Case reports ) - Management of PSA progression after topical treatment of prostate cancer
doc. MUDr. Pavol Dubinský, PhD., MHA
(S1/2020, Case reports ) - Správa z XXI. košických chemoterapeutických dní
MUDr. Jana Jankurová
(1/2018, Events ) - Glukokortikoidy v liečbe kastračne-rezistentného karcinómu prostaty a mechanizmy rezistencie na androgénnu blokádu
JUDr. MUDr. Patrik Palacka, PhD., MPH, MBA, LL.M.
(4/2018, Review articles ) - Androgen deprivation therapy and radiotherapy of prostate cancer
doc. MUDr. Pavol Dubinský, PhD.
(5/2018, Review articles ) - The latest advances in the diagnosis and treatment of prostate cancer
MUDr. Peter Leško, PhD.
(3/2026, Main topic )
- Nové liečivá v EÚ registrované v roku 2013 (II.)
PharmDr. Peter Stanko
(1/2014, New drugs ) - Pharmacokinetic drug-drug interactions of direct oral anticoagulants
PharmDr. Josef Suchopár, MUDr. Michal Prokeš, Mgr. Štěpán Suchopár
(1-2/2026, Current pharmacotherapy )